Germany's regulator reports 31 cases of blood disorder after AstraZeneca shot(reuters.com)
reuters.com
Germany's regulator reports 31 cases of blood disorder after AstraZeneca shot
https://www.reuters.com/article/idUSS8N2KO06C
3 comments
31 cases out of how many shots? A million or 50? It would always be good to have a reference point.
According to NRK, Der Spiegel has reported that 1.78 million women below 70 years and 864.000 men have had the vaccine. The nine cases thus suggest a risk of 1 in 61.400 for blood clots in women and 1 in 432.000 for men.
Source (Norwegian): https://www.nrk.no/norge/der-spiegel_-31-tilfeller-av-blodpr...
Source (Norwegian): https://www.nrk.no/norge/der-spiegel_-31-tilfeller-av-blodpr...
This what Reuters reports. They use The Paul Ehrlich Institute (PEI) as a source.
If you go to PEI to check it out, their newsroom has article titled:
"COVID-19 Vaccine AstraZeneca – Safety Assessment Result: The Vaccine is Safe and Effective in the Fight against COVID-19" https://www.pei.de/EN/newsroom/hp-news/2021/210319-covid-19-...
Cutting and pasting from the article:
>The safety assessment by the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) confirms the positive benefit-risk ratio of COVID-19 Vaccine AstraZeneca. As a risk-mitigation warning, the SmPC includes the fact that in very rare cases, specific thromboses are found in the period up to 16 days after vaccination. Based on the positive safety assessment by the EMA, Germany will resume vaccination with the COVID-19 Vaccine AstraZeneca starting 19 March 2021. Those willing to be vaccinated will be informed about the above cases during vaccination education. Medical doctors can find information on the website of the Paul-Ehrlich-Institut.
>... The vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in vaccinated individuals. There is no evidence of a quality defect - that is, an association of specific batches or manufacturing at specific sites of the vaccine with the observed thromboembolic events.
>... A very rare form of thrombosis (primarily cerebral venous thrombosis) associated with platelet deficiency (thrombocytopenia) was observed in a very small number of vaccinated individuals predominantly under the age of 55 years following vaccination with COVID-19 Vaccine AstraZeneca.
>... This very rare coagulation disorder occurred more frequently among those vaccinated than would be expected numerically based on the rarity of this clotting disorder without vaccination. There is currently no evidence that the occurrence of these clotting disorders was caused by the vaccine.
If you go to PEI to check it out, their newsroom has article titled:
"COVID-19 Vaccine AstraZeneca – Safety Assessment Result: The Vaccine is Safe and Effective in the Fight against COVID-19" https://www.pei.de/EN/newsroom/hp-news/2021/210319-covid-19-...
Cutting and pasting from the article:
>The safety assessment by the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) confirms the positive benefit-risk ratio of COVID-19 Vaccine AstraZeneca. As a risk-mitigation warning, the SmPC includes the fact that in very rare cases, specific thromboses are found in the period up to 16 days after vaccination. Based on the positive safety assessment by the EMA, Germany will resume vaccination with the COVID-19 Vaccine AstraZeneca starting 19 March 2021. Those willing to be vaccinated will be informed about the above cases during vaccination education. Medical doctors can find information on the website of the Paul-Ehrlich-Institut.
>... The vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in vaccinated individuals. There is no evidence of a quality defect - that is, an association of specific batches or manufacturing at specific sites of the vaccine with the observed thromboembolic events.
>... A very rare form of thrombosis (primarily cerebral venous thrombosis) associated with platelet deficiency (thrombocytopenia) was observed in a very small number of vaccinated individuals predominantly under the age of 55 years following vaccination with COVID-19 Vaccine AstraZeneca.
>... This very rare coagulation disorder occurred more frequently among those vaccinated than would be expected numerically based on the rarity of this clotting disorder without vaccination. There is currently no evidence that the occurrence of these clotting disorders was caused by the vaccine.